Biocept, Inc.
BIOCQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -97.63% | -89.62% | -57.78% | -38.06% | 4.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.63% | -89.62% | -57.78% | -38.06% | 4.21% |
| Cost of Revenue | -60.50% | -45.94% | -24.69% | -9.49% | 22.61% |
| Gross Profit | -181.48% | -159.76% | -111.00% | -76.52% | -22.17% |
| SG&A Expenses | -44.23% | -34.02% | 11.01% | 19.74% | 32.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.44% | -38.41% | -9.14% | 3.57% | 27.69% |
| Operating Income | -115.82% | -411.32% | -1,227.14% | -1,170.80% | -693.27% |
| Income Before Tax | -95.44% | -394.69% | -1,093.04% | -1,331.69% | -613.05% |
| Income Tax Expenses | -200.00% | -200.00% | -200.00% | -- | -- |
| Earnings from Continuing Operations | -93.11% | -384.95% | -1,035.82% | -1,337.79% | -618.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -93.11% | -384.95% | -1,035.82% | -1,337.79% | -618.72% |
| EBIT | -115.82% | -411.32% | -1,227.14% | -1,170.80% | -693.27% |
| EBITDA | -128.10% | -522.85% | -3,346.48% | -736.92% | -2,121.77% |
| EPS Basic | -78.99% | -347.09% | -1,089.05% | -1,038.82% | -468.57% |
| Normalized Basic EPS | -81.20% | -355.60% | -1,152.20% | -1,034.04% | -464.15% |
| EPS Diluted | -79.96% | -345.10% | -1,033.65% | -1,092.37% | -429.30% |
| Normalized Diluted EPS | -81.20% | -355.60% | -1,121.54% | -1,070.34% | -444.54% |
| Average Basic Shares Outstanding | 25.47% | 9.69% | 14.79% | 21.47% | 23.11% |
| Average Diluted Shares Outstanding | 25.47% | 9.69% | 14.27% | 20.44% | 22.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |